Nuvectis Pharma to Participate in the Maxim Growth Summit 2026

Fri, 09 Oct 2026 08:00:00 -0400

Fort Lee, NJ, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York.

Conference Details:

Panel Discussion:

Immunology & Inflammation Therapies

Presenter:

Ron Bentsur, Chairman and CEO

Date and

Nuvectis Pharma to Participate in the Maxim Growth Summit 2026

Fri, 09 Oct 2026 08:00:00 -0400

Conference Details:

Panel Discussion:

Immunology & Inflammation Therapies

Presenter:

Ron Bentsur, Chairman and CEO

Date and

Nuvectis drug NXP200 gets China breakthrough therapy status

Thu, 24 Sep 2026 08:01:53 -0400

Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced that its drug candidate NXP200 (HSK42360) has received Breakthrough Therapy Designation (BTD) from China's Center for Drug Evaluation (CDE) for the treatment of patients with BRAF V600-mutant, recurrent or progressive high-grade glioma.

NXP200 is an oral, brain-penetrant BRAF inhibitor designed to block the BRAF pathway without triggering paradoxical activation associated with first-generation BRAF inhibitors. The drug has shown single-agent clinical activity in heavily pre-treated patients, including those previously treated with BRAF inhibitors, across primary central nervous system tumors and other cancer types including non-small cell lung, colorectal, and papillary thyroid cancers.

In June 2026, Nuvectis in-licensed

Nuvectis drug NXP200 gets China breakthrough therapy status

Thu, 24 Sep 2026 08:01:53 -0400

In June 2026, Nuvectis in-licensed

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma

Thu, 24 Sep 2026 08:00:00 -0400

Fort Lee, NJ, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, announced today that NXP200 (HSK42360), an oral, brain-penetrant, paradox-breaker BRAF inhibitor, has been granted Breakthrough Therapy Designation (BTD) for the treatment of patients with BRAF V600-mutant, recurrent or progressive high-grade glioma by China’s Center for Drug Evaluation (CDE).

NXP200 is a paradox-breaking BRAF inhibitor designed to block the BRAF pathway without triggering paradoxical activation that is seen with first-generation BRAF

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma

Thu, 24 Sep 2026 08:00:00 -0400

NXP200 is a paradox-breaking BRAF inhibitor designed to block the BRAF pathway without triggering paradoxical activation that is seen with first-generation BRAF

Nuvectis Pharma To Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 08:00:00 -0400

Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the following upcoming investor conferences:

2026 Cantor Global Healthcare Conference: Fireside Chat, Friday, September 11, 2026 at 9:10 AM ET. Webcast link: Cantor Fireside Chat.
H.C. Wainwright 28^th Annual Global Investment Conference: Company Presentation, Monday, September 14, 2026 at 12:00 PM ET. Webcast link:

Nuvectis Pharma To Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 08:00:00 -0400

2026 Cantor Global Healthcare Conference: Fireside Chat, Friday, September 11, 2026 at 9:10 AM ET. Webcast link: Cantor Fireside Chat.
H.C. Wainwright 28^th Annual Global Investment Conference: Company Presentation, Monday, September 14, 2026 at 12:00 PM ET. Webcast link:

Lucid Capital Markets Assumes Nuvectis Pharma (NVCT) at Buy

Tue, 01 Sep 2026 06:12:02 -0400

Lucid Capital Markets analyst Elemer Piros assumes coverage on Nuvectis Pharma (NASDAQ: NVCT) with a Buy rating and a price target of $40.00.

The analyst comments "We estimate NXP100 could achieve net sales of ~$1B in the US (2035) and ~$750M (2036) across EU5 countries. Given NXP100’s approval in China, late-stage efficacy broadly comparable to Fabhalta, and validation of Factor B as a therapeutic target, we apply an 80% PoS, with US regulatory execution representing the primary remaining risk. Our probabilityadjusted, fully taxed NPV is ~$1.4B, supporting our 12-month price target of $40 per share. Factors that could impede shares from

Lucid Capital Markets Assumes Nuvectis Pharma (NVCT) at Buy

Tue, 01 Sep 2026 06:12:02 -0400

Lucid Capital Markets analyst Elemer Piros assumes coverage on Nuvectis Pharma (NASDAQ: NVCT) with a Buy rating and a price target of $40.00.

Cantor Fitzgerald Starts Nuvectis Pharma (NVCT) at Overweight

Mon, 24 Aug 2026 06:19:18 -0400

Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Nuvectis Pharma (NASDAQ: NVCT) with a Overweight rating.

For an analyst ratings summary and ratings history on Nuvectis Pharma click here. For more ratings news on Nuvectis Pharma click here.

Shares of Nuvectis Pharma closed at $23.56 yesterday.

Nuvectis Pharma (NVCT) files $200M mixed shelf

Fri, 21 Aug 2026 16:41:25 -0400

Nuvectis Pharma (NASDAQ: NVCT) filed $200,000,000 mixed shelf of:

Common Stock

Preferred Stock

Warrants

Debt Securities

Units

Nuvectis Pharma (NVCT) files $200M mixed shelf

Fri, 21 Aug 2026 16:41:25 -0400

Nuvectis Pharma (NASDAQ: NVCT) filed $200,000,000 mixed shelf of:

Common Stock

Preferred Stock

Warrants

Debt Securities

Units

Form S-3 Nuvectis Pharma, Inc.

Fri, 21 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260821/26961927.html

Form S-3 Nuvectis Pharma, Inc.

Fri, 21 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260821/26961927.html

Form 8-K Nuvectis Pharma, Inc. For: Jul 20

Fri, 21 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260821/26961822.html

Form 8-K Nuvectis Pharma, Inc. For: Jul 20

Fri, 21 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260821/26961822.html

Form SCHEDULE 13G Nuvectis Pharma, Inc. Filed by: Soleus Private Equity Fund III, L.P.

Thu, 06 Aug 2026 11:29:00 -0400

si-local-file:///var/storage/secattach/20260806/26881717.html

Form SCHEDULE 13G Nuvectis Pharma, Inc. Filed by: Soleus Private Equity Fund III, L.P.

Thu, 06 Aug 2026 11:29:00 -0400

si-local-file:///var/storage/secattach/20260806/26881717.html

Form 4 Nuvectis Pharma, Inc. For: Aug 03 Filed by: Carson Michael J.

Wed, 05 Aug 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260805/26876077.html

Form 4 Nuvectis Pharma, Inc. For: Aug 03 Filed by: Carson Michael J.

Wed, 05 Aug 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260805/26876077.html

Form 10-Q Nuvectis Pharma, Inc. For: Jun 30

Tue, 04 Aug 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260804/26862954.html

Form 10-Q Nuvectis Pharma, Inc. For: Jun 30

Tue, 04 Aug 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260804/26862954.html

Form 8-K Nuvectis Pharma, Inc. For: Aug 04

Tue, 04 Aug 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260804/26862263.html

Form 8-K Nuvectis Pharma, Inc. For: Aug 04

Tue, 04 Aug 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260804/26862263.html

StreetInsider.com News Articles

Nuvectis Pharma to Participate in the Maxim Growth Summit 2026

Nuvectis Pharma to Participate in the Maxim Growth Summit 2026

Nuvectis drug NXP200 gets China breakthrough therapy status

Nuvectis drug NXP200 gets China breakthrough therapy status

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma

Nuvectis Pharma To Participate in Upcoming Investor Conferences

Nuvectis Pharma To Participate in Upcoming Investor Conferences

Lucid Capital Markets Assumes Nuvectis Pharma (NVCT) at Buy

Lucid Capital Markets Assumes Nuvectis Pharma (NVCT) at Buy

Cantor Fitzgerald Starts Nuvectis Pharma (NVCT) at Overweight

Nuvectis Pharma (NVCT) files $200M mixed shelf

Nuvectis Pharma (NVCT) files $200M mixed shelf

Form S-3 Nuvectis Pharma, Inc.

Form S-3 Nuvectis Pharma, Inc.

Form 8-K Nuvectis Pharma, Inc. For: Jul 20

Form 8-K Nuvectis Pharma, Inc. For: Jul 20

Form SCHEDULE 13G Nuvectis Pharma, Inc. Filed by: Soleus Private Equity Fund III, L.P.

Form SCHEDULE 13G Nuvectis Pharma, Inc. Filed by: Soleus Private Equity Fund III, L.P.

Form 4 Nuvectis Pharma, Inc. For: Aug 03 Filed by: Carson Michael J.

Form 4 Nuvectis Pharma, Inc. For: Aug 03 Filed by: Carson Michael J.

Form 10-Q Nuvectis Pharma, Inc. For: Jun 30

Form 10-Q Nuvectis Pharma, Inc. For: Jun 30

Form 8-K Nuvectis Pharma, Inc. For: Aug 04

Form 8-K Nuvectis Pharma, Inc. For: Aug 04